1. Search Result
Search Result
Results for "

glycine receptor

" in MedChemExpress (MCE) Product Catalog:

104

Inhibitors & Agonists

1

Biochemical Assay Reagents

7

Peptides

21

Natural
Products

2

Recombinant Proteins

35

Isotope-Labeled Compounds

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-150138

    GV 150526

    iGluR Neurological Disease
    Gavestinel (GV 150526) is a selective and potent the glycine site of the NMDA receptor antagonist. Gavestinel has neuroprotectant effects .
    Gavestinel
  • HY-107782

    GABA Receptor Neurological Disease
    Picrotin is an active compound, also is one of the composition of picrotoxin (an antagonist of GABAA receptors (GABAARs) and glycine receptors (GlyRs)). Picrotin has sensitivity for GlyRs with IC50 values range from 5.2 μM to 106 μM. Picrotin can be used for the research of neurotransmission .
    Picrotin
  • HY-Y0966S8

    Endogenous Metabolite iGluR Neurological Disease
    Glycine-d5 is the deuterium labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
    Glycine-d5
  • HY-Y0966S1

    Isotope-Labeled Compounds Endogenous Metabolite iGluR Neurological Disease
    Glycine-d2 is the deuterium labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
    Glycine-d2
  • HY-Y0966S2

    Endogenous Metabolite iGluR Neurological Disease
    Glycine-2- 13C is the 13C-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
    Glycine-2-13C
  • HY-Y0966S4

    Endogenous Metabolite iGluR Neurological Disease
    Glycine-1- 13C is the 13C-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
    Glycine-1-13C
  • HY-Y0966S7

    Isotope-Labeled Compounds Endogenous Metabolite iGluR Neurological Disease
    Glycine-2- 13C, 15N is the 13C- and 15N-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
    Glycine-2-13C,15N
  • HY-147367

    Others Neurological Disease
    AM-1488 is a potent, orally active glycine receptor (GlyR) potentiator (hGlyRα3 EC50=0.45 μM) .
    AM-1488
  • HY-107782R

    GABA Receptor Reference Standards Neurological Disease
    Picrotin (Standard) is the analytical standard of Picrotin. This product is intended for research and analytical applications. Picrotin is an active compound, also is one of the composition of picrotoxin (an antagonist of GABAA receptors (GABAARs) and glycine receptors (GlyRs)). Picrotin has sensitivity for GlyRs with IC50 values range from 5.2 μM to 106 μM. Picrotin can be used for the research of neurotransmission .
    Picrotin (Standard)
  • HY-Y0966S10

    Isotope-Labeled Compounds Endogenous Metabolite iGluR Cancer
    Glycine-d3 is the deuterium labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
    Glycine-d3
  • HY-Y0966S5

    Isotope-Labeled Compounds Endogenous Metabolite iGluR Neurological Disease
    Glycine-1- 13C, 15N is the 13C- and 15N-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
    Glycine-1-13C,15N
  • HY-W424730

    iGluR Others
    HA-966 hydrochloride is a glycine site antagonist of the NMDA receptor, exhibiting non-competitive antagonism on NMDA responses. HA-966 hydrochloride effectively blocks the enhancement of NMDA responses by glycine in a competitive manner. HA-966 hydrochloride plays a significant role in mediating the antagonist action at the glycine modulatory site of the NMDA receptor.
    HA-966 hydrochloride
  • HY-16312
    MDL-29951
    3 Publications Verification

    iGluR Neurological Disease
    MDL-29951 is a novel glycine antagonist of NMDA receptor activation, with Ki of 0.14 μM for [ 3H]glycine binding in vitro and in vivo.
    MDL-29951
  • HY-Y0966S

    Endogenous Metabolite iGluR Neurological Disease
    Glycine- 15N is the 15N-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors .
    Glycine-15N
  • HY-Y0966S3

    Isotope-Labeled Compounds Endogenous Metabolite iGluR Neurological Disease
    Glycine- 13C2 is the 13C-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
    Glycine-13C2
  • HY-Y0966R

    Reference Standards Endogenous Metabolite iGluR VEGFR Neurological Disease
    Glycine (Standard) is the analytical standard of Glycine. This product is intended for research and analytical applications. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis .
    Glycine (Standard)
  • HY-15085

    iGluR Neurological Disease
    MDL 105519 is a potent and selective antagonist of glycine binding to the NMDA receptor.
    MDL 105519
  • HY-Y0966S9

    Isotope-Labeled Compounds Endogenous Metabolite iGluR Neurological Disease
    Glycine- 15N,d2 is the deuterium and 15N-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
    Glycine-15N,d2
  • HY-Y0966S6

    Endogenous Metabolite iGluR Neurological Disease
    Glycine- 13C2, 15N is the 13C- and 15N-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
    Glycine-13C2,15N
  • HY-16569
    Colchicine
    Maximum Cited Publications
    44 Publications Verification

    Microtubule/Tubulin NOD-like Receptor (NLR) Autophagy Apoptosis Cancer
    Colchicine, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC50 of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine has extensive anti-inflammatory, immunosuppressive and strong anti-fibrosis effects and has the potential for gouty arthritis research .
    Colchicine
  • HY-107705

    iGluR Neurological Disease
    NMDAR antagonist 4 (Compound 8) is the antagonist for NMDA receptor that binds NMDA receptor on glycine site with Ki >100 μM .
    NMDAR antagonist 4
  • HY-101037
    Sarcosine
    1 Publications Verification

    N-Methylglycine; Sarcosin

    Endogenous Metabolite GlyT Cancer
    Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .
    Sarcosine
  • HY-Y0966
    Glycine
    5+ Cited Publications

    Endogenous Metabolite iGluR VEGFR Neurological Disease
    Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis .
    Glycine
  • HY-Y0966S11

    iGluR Endogenous Metabolite Neurological Disease
    Glycine- 13C2, 15N,d2 is the deuterium, 13C and 15N labeled Glycine . Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors .
    Glycine-13C2,15N,d2
  • HY-30006

    iGluR Neurological Disease
    1-Aminocyclobutanecarboxylic acid is a NMDA receptor partial agonist acting at the glycine site, NR1 .
    1-Aminocyclobutanecarboxylic acid
  • HY-16569R

    Reference Standards Microtubule/Tubulin NOD-like Receptor (NLR) Autophagy Apoptosis Cancer
    Colchicine (Standard) is the analytical standard of Colchicine. This product is intended for research and analytical applications. Colchicine, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC50 of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine has extensive anti-inflammatory, immunosuppressive and strong anti-fibrosis effects and has the potential for gouty arthritis research .
    Colchicine (Standard)
  • HY-41700

    (R)-Alanine; Ba 2776; D-α-Alanine

    Endogenous Metabolite Neurological Disease
    D-Alanine is a weak GlyR (inhibitory glycine receptor) and PMBA agonist, with an EC50 of 9 mM for GlyR .
    D-Alanine
  • HY-101037S1

    N-Methylglycine-d3; Sarcosin-d3

    Isotope-Labeled Compounds Endogenous Metabolite GlyT Cancer
    Sarcosine-d3 is the deuterium labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .
    Sarcosine-d3
  • HY-101037S

    N-Methylglycine-15N; Sarcosin-15N

    Endogenous Metabolite GlyT Cancer
    Sarcosine- 15N is the 15N-labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .
    Sarcosine-15N
  • HY-117547

    ACEA-1021

    iGluR Neurological Disease
    Licostinel (ACEA-1021) is a glycine receptor antagonist (IC50: 59 nM). Licostinel has neuroprotective activity .
    Licostinel
  • HY-101037R

    N-Methylglycine (Standard); Sarcosin (Standard)

    Reference Standards Endogenous Metabolite GlyT Cancer
    Sarcosine (Standard) is the analytical standard of Sarcosine. This product is intended for research and analytical applications. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .
    Sarcosine (Standard)
  • HY-100803
    Hypotaurine
    3 Publications Verification

    2-Aminoethanesulfinic acid

    Endogenous Metabolite Neurological Disease
    Hypotaurine (2-aminoethanesulfinic acid), an intermediate in taurine biosynthesis from cysteine in astrocytes, is an endogenous inhibitory amino acid of the glycine receptor. Antioxidant .
    Hypotaurine
  • HY-16728
    Rapastinel
    1 Publications Verification

    GLYX-13

    iGluR Neurological Disease
    Rapastinel (GLYX-13) is an N-methyl-D-aspartate receptor (NMDAR) modulator that has characteristics of a glycine site partial agonist.
    Rapastinel
  • HY-I0096

    iGluR HIV HIV Integrase Neurological Disease
    Indole-2-carboxylic acid (I2CA) is a competitive antagonist of the glycine site of the NMDA receptor (Ki=15 μM, 5-fluoro-I2CA) and an inhibitor of HIV-1 integrase. Indole-2-carboxylic acid is selective for the glycine site of the NMDA receptor and blocks the enhancement of NMDA receptor by competitively inhibiting the binding of glycine to the NMDA receptor. Indole-2-carboxylic acid can also inhibit the strand transfer activity of HIV-1 integrase by chelating Mg 2+ at the active site of integrase and interacting with the hydrophobic cavity. Indole-2-carboxylic acid can be used in the study of neurological diseases (such as stroke, epilepsy) and HIV-1 infection .
    Indole-2-carboxylic acid
  • HY-107701

    iGluR Neurological Disease
    CGP 78608 hydrochloride is a highly potent and selective antagonist at the glycine-binding site of the NMDA receptor, with an IC50 of 6 nM. CGP 78608 hydrochloride acts as a potentiator of GluN1/GluN3A-mediated glycine currents, with an estimated EC50 in the low nM range (26.3 nM). Anticonvulsant activity .
    CGP 78608 hydrochloride
  • HY-16728B
    Rapastinel Trifluoroacetate
    1 Publications Verification

    GLYX-13 Trifluoroacetate

    iGluR Neurological Disease
    Rapastinel Trifluoroacetate (GLYX-13 Trifluoroacetate) is an NMDA receptor modulator with glycine-site partial agonist properties. Rapastinel Trifluoroacetate has the potential for major depressive disorder treatment.
    Rapastinel Trifluoroacetate
  • HY-155049

    iGluR Neurological Disease
    NMDA receptor antagonist 6 (compound 13b) is an antagonist of NMDA receptor, targeting to the glycine binding site. NMDA receptor antagonist 6 shows cytoneuroprotective potency, and protects PC12 cells against NMDA-induced injury and cell apoptosis .
    NMDA receptor antagonist 6
  • HY-107701A

    iGluR Neurological Disease
    CGP 78608 is a highly potent and selective antagonist at the glycine-binding site of the NMDA receptor, with an IC50 of 6 nM. CGP 78608 acts as a potentiator of GluN1/GluN3A-mediated glycine currents, with an estimated EC50 in the low nM range (26.3 nM). CGP 78608 has anticonvulsant activities .
    CGP-78608
  • HY-114753A

    CR-2249 hydrochloride; XY-2401 hydrochloride

    iGluR Neurological Disease
    Neboglamine (CR-2249, XY-2401) hydrochloride is an orally active NMDA receptor glycine site positive modulator that can be used in schizophrenia research .
    Neboglamine hydrochloride
  • HY-41700S2

    (R)-Alanine-d1; Ba 2776-d1; D-α-Alanine-d1

    Isotope-Labeled Compounds Endogenous Metabolite Neurological Disease
    D-Alanine-d is the deuterium labeled D-Alanine. D-Alanine is a weak GlyR (inhibitory glycine receptor) and PMBA agonist, with an EC50 of 9 mM for GlyR .
    D-Alanine-d1
  • HY-100839

    D,L-(tetrazol-5-yl)glycine; LY 285265

    iGluR Neurological Disease
    (RS)-(Tetrazol-5-yl)glycine (D,L-(tetrazol-5-yl)glycine) is a highly potent and selective N-methyl-D-aspartate (NMDA) receptor agonist . (RS)-(Tetrazol-5-yl)glycine has EC50s of 99 nM, 1.7 μM for GluN1/GluN2D and GluN1/GluN2A, respectively . (RS)-(Tetrazol-5-yl)glycine induces seizure responses and Fos in mice .
    (RS)-(Tetrazol-5-yl)glycine
  • HY-107700

    GV 150526A

    iGluR Cardiovascular Disease
    Gavestinel (GV 150526A) is a potent, selective, orally active and non-competitive antagonist of NMDA receptor. Gavestinel binds to the glycine site of the NMDA receptor, with a pKi of 8.5. Gavestinel can be used for the research of acute ischemic stroke .
    Gavestinel sodium salt
  • HY-N0301

    GABA Receptor Neurological Disease Inflammation/Immunology
    Thiocolchicoside is a competitive γ-aminobutyric acid type A (GABAA) receptor antagonist and glycine receptor agonist in the central nervous system. Thiocolchicoside is a semisynthetic sulfur derivative of colchicoside. Thiocolchicoside is a muscle relaxant and has anti-inflammatory, and analgesic properties .
    Thiocolchicoside
  • HY-41700S3

    (R)-Alanine-d7; Ba 2776-d7; D-α-Alanine-d7

    Endogenous Metabolite Neurological Disease
    D-Alanine-d7 is the deuterium labeled D-Alanine. D-Alanine is a weak GlyR (inhibitory glycine receptor) and PMBA agonist, with an EC50 of 9 mM for GlyR.
    D-Alanine-d7
  • HY-41700S1

    (R)-Alanine-d4; Ba 2776-d4; D-α-Alanine-d4

    Endogenous Metabolite Others
    D-Alanine-d4 is the deuterium labeled D-Alanine. D-Alanine is a weak GlyR (inhibitory glycine receptor) and PMBA agonist, with an EC50 of 9 mM for GlyR.
    D-Alanine-d4
  • HY-41700S

    (R)-Alanine-d3; Ba 2776-d3; D-α-Alanine-d3

    Isotope-Labeled Compounds Endogenous Metabolite Others
    D-Alanine-d3 is the deuterium labeled D-Alanine. D-Alanine is a weak GlyR (inhibitory glycine receptor) and PMBA agonist, with an EC50 of 9 mM for GlyR.
    D-Alanine-d3
  • HY-W748519

    N-Methylglycine-13C3; Sarcosin-13C3

    Isotope-Labeled Compounds GlyT Endogenous Metabolite Cancer
    Sarcosine- 13C3 (N-Methylglycine- 13C3; Sarcosin- 13C3) is the 13C-labeled Sarcosine (HY-101037). Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .
    Sarcosine-13C3
  • HY-101101

    iGluR Neurological Disease
    L-701252 is a potent antagonist of glycine site NMDA receptor with an IC50 of 420 nM. L-701252 provides a small degree of neuroprotection in global cerebral ischaemia .
    L-701252
  • HY-106968

    iGluR Neurological Disease
    ZD-9379 is a potent, orally active, and brain penetrant full antagonist at the glycine site of the NMDA receptor. ZD-9379 has neuroprotective effect .
    ZD-9379
  • HY-113204
    N-Oleoyl glycine
    1 Publications Verification

    Endogenous Metabolite Cannabinoid Receptor Akt Metabolic Disease
    N-Oleoyl glycine is a lipoamino acid, which stimulates adipogenesis associated with activation of CB1 receptor and Akt signaling pathway in 3T3-L1 adipocyte.
    N-Oleoyl glycine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: